|
Feb 28
|
Royalty Pharma to Present at TD Cowen’s 44th Annual Health Care Conference
|
|
Jan 8
|
Royalty Pharma Highlights Accomplishments and Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference
|
|
Nov 27
|
Royalty Pharma to Present at the Evercore ISI 6th Annual HealthCONx Conference
|
|
Nov 26
|
Royalty Pharma plc (NASDAQ:RPRX) is a favorite amongst institutional investors who own 69%
|
|
Nov 13
|
Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai Program
|
|
Nov 13
|
Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program
|
|
Nov 8
|
Royalty Pharma Reports Third Quarter 2023 Results
|
|
Sep 12
|
Are Royalty Pharma plc's (NASDAQ:RPRX) Mixed Financials Driving The Negative Sentiment?
|
|
Aug 24
|
Royalty Pharma and Ferring Pharmaceuticals Enter Into US $500 Million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (Nadofaragene Firadenovec-Vncg)
|
|
Jul 18
|
Royalty Pharma to Announce Second Quarter 2023 Financial Results on August 8, 2023
|
|
Jul 17
|
Royalty Pharma Declares Third Quarter 2023 Dividend
|